Product image of Nexpovio (Selinexor) supplied by GNH India

Nexpovio

Active Ingredient:
Selinexor
Origin:
EU

Nexpovio (Selinexor)

Selinexor, the active ingredient in Nexpovio, is a selective inhibitor of nuclear export (SINE) presented as an oral tablet for oral use. It is indicated for relapsed or refractory multiple myeloma in combination with dexamethasone and bortezomib.
GNH India supplies Nexpovio as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Manufacturer / TM Owner

Stemline Therapeutics B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Selinexor acts on malignant cells by blocking nuclear export pathways, making it a key therapy in certain blood cancers.

  • Relapsed or refractory multiple myeloma: improves disease control when combined with dexamethasone and bortezomib.
  • Relapsed or refractory diffuse large B‑cell lymphoma: used with standard chemotherapy regimens to enhance response rates.
  • Relapsed or refractory solid tumours (clinical investigation): evaluated in trials as part of combination strategies to overcome resistance.

How It Works

  • Selinexor selectively inhibits exportin‑1 (XPO1), the primary nuclear export protein. By blocking XPO1, tumor‑suppressor proteins, growth regulators and apoptotic factors remain in the nucleus, restoring their function and triggering programmed cell death in malignant cells while sparing most normal tissues.

Side Effects

Selinexor is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Fatigue: persistent tiredness affecting daily activities.
  • Nausea: upset stomach often occurring after dosing.
  • Thrombocytopenia: reduced platelet count leading to easy bruising.
  • Anemia: low red blood cell levels causing weakness.
  • Neutropenia: decreased neutrophils increasing infection risk.
  • Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects

  • Severe infections: opportunistic or bacterial infections requiring hospitalization.
  • Hepatic dysfunction: elevated liver enzymes or hepatitis.
  • Cardiac arrhythmias: irregular heart rhythms, especially in patients with pre‑existing conditions.
  • Pulmonary embolism: blood clot in the lungs.
  • Tumor lysis syndrome: rapid tumour cell breakdown causing metabolic disturbances.
  • Hyponatremia: dangerously low sodium levels.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate several safety parameters.

  • Monitor blood counts: regular CBC to detect cytopenias.
  • Assess liver function: periodic LFTs to identify hepatic toxicity.
  • Evaluate infection risk: avoid use in patients with active uncontrolled infections.
  • Review concomitant QT‑prolonging agents: consider ECG monitoring.
  • Pregnancy: risk unknown; avoid unless benefits outweigh potential harm.
  • Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Selinexor may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin): may reduce Selinexor exposure.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase toxicity risk.
  • QT‑prolonging drugs (e.g., amiodarone): can exacerbate cardiac rhythm disturbances.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (e.g., warfarin): monitor INR for bleeding risk.
  • Other antineoplastic agents metabolized by CYP3A4: adjust dosing as needed.
  • Immunosuppressants (e.g., cyclosporine): watch for enhanced myelosuppression.

Frequently Asked Questions

Nexpovio contains the active ingredient Selinexor and is approved for the treatment of relapsed or refractory multiple myeloma, typically in combination with dexamethasone and bortezomib. It is also authorized for certain aggressive lymphomas and is being studied in solid‑tumour indications as part of combination regimens.

Selinexor blocks the nuclear export protein exportin‑1 (XPO1). This inhibition traps tumor‑suppressor proteins, growth regulators and apoptotic factors inside the nucleus, restoring their activity and leading to programmed cell death of cancer cells while largely sparing normal cells.

The prescribed dose of Selinexor is individualized by the treating physician based on the patient’s disease status, prior therapies, organ function and tolerance. It is administered orally as a tablet, and the exact regimen is determined by the clinician’s assessment.

Safety data for Selinexor during pregnancy and lactation are limited. The drug is classified as contraindicated unless the potential benefit justifies the risk. Women of child‑bearing potential should use effective contraception, and breastfeeding is generally discouraged while on therapy.

To place an order, submit an enquiry on the Nexpovio product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nexpovio offers a novel mechanism—nuclear export inhibition—unlike proteasome inhibitors or immunomodulatory drugs. It is often used after patients have progressed on standard regimens, providing an additional line of therapy. While effective, its safety profile includes notable cytopenias, so clinicians balance benefits against potential hematologic toxicity.

Store Nexpovio tablets at ambient temperature, below 25 °C, in the original blister pack. Protect the product from moisture, excessive heat and direct sunlight. Keep out of reach of children and do not use if the packaging is damaged.

Nexpovio is taken orally as a whole tablet, usually on an empty stomach unless the prescriber advises otherwise. The tablet should be swallowed with water and not chewed, crushed or split, to ensure consistent absorption.

Serious adverse events include severe infections, significant drops in blood cell counts (especially platelets and neutrophils), hepatic injury, cardiac arrhythmias, pulmonary embolism and tumor‑lysis syndrome. Patients should be monitored closely for signs of infection, bleeding, liver dysfunction and cardiac abnormalities.

Nexpovio is contraindicated in individuals with known hypersensitivity to Selinexor or any tablet excipients, those with uncontrolled active infections, severe hepatic impairment, and pregnant women unless the therapeutic benefit outweighs the risk. Caution is also advised for patients with pre‑existing cardiac conditions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Selinexor

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT